Metronidazol Aurovitas

Metronidazole, the active ingredient in Metronidazol Aurovitas, is a nitroimidazole presented as an oral dosage form for systemic use. It is employed to treat infections caused by anaerobic bacteria and certain protozoa in adult patients and is commonly prescribed in outpatient settings under medical supervision.

GNH USA supplies Metronidazol Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and regulatory requirements across EU markets. Clients benefit from reliable logistics and comprehensive documentation for import clearance.

Metronidazole is indicated for a range of infections caused by anaerobic bacteria and susceptible protozoa. - Bacterial vaginosis: restores normal vaginal flora by eliminating anaerobic bacteria. - Trichomoniasis: eradicates Trichomonas vaginalis, relieving symptoms and preventing recurrence. - Amoebiasis: treats intestinal Entamoeba histolytica infection, reducing dysentery and tissue invasion. - Giardiasis: clears Giardia lamblia from the gastrointestinal tract, alleviating diarrhea and malabsorption. - Anaerobic bacterial infections: combats mixed anaerobic infections such as intra‑abdominal or pelvic infections.

Metronidazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild stomach upset that may improve when taken with food. - Metallic taste: a persistent metallic sensation in the mouth during therapy. - Diarrhea: loose stools that can lead to dehydration if not managed. - Headache: mild to moderate head pain that may fluctuate during treatment.

Serious or Rare Side Effects: - Seizures: convulsions that require immediate medical attention and discontinuation. - Peripheral neuropathy: tingling, numbness or burning sensations in the hands or feet. - Severe allergic reactions: rash, swelling, breathing difficulty or anaphylaxis.

Before initiating Metronidazol Aurovitas, clinicians should evaluate several safety considerations. - Renal function: assess kidney performance and adjust dose if impairment is present. - Hepatic function: monitor liver enzymes, especially in patients with pre‑existing liver disease. - Alcohol consumption: advise patients to avoid alcohol due to a disulfiram‑like reaction. - Central nervous system disorders: use cautiously in patients with seizure history or CNS disease. - Neuropathy monitoring: watch for early signs of peripheral neuropathy during prolonged therapy. - Store at below 25°C: keep in the original packaging, protect from moisture and heat.

Metronidazol Aurovitas can interact with several medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Alcohol: may cause severe flushing, tachycardia and vomiting (disulfiram‑like reaction). - Warfarin: potentiates anticoagulant effect, increasing bleeding risk. - Lithium: can raise lithium levels, leading to toxicity.

Moderate Interactions (Monitor Closely): - Phenytoin: may reduce metronidazole concentrations, decreasing effectiveness. - Cimetidine: can increase metronidazole plasma levels, heightening side‑effect potential. - Carbamazepine: may lower metronidazole levels, requiring clinical monitoring.